Navigation Links
Clinical observation leads to lung cancer discovery
Date:3/7/2011

at ALK positive patients can be super sensitive to pemetrexed may have multiple implications for the 20,000 patients who are thought to develop this subtype of lung cancer every year in the United States.

"To get a new drug, like crizotinib, approved, it is usually compared to some standard chemotherapy. These new results highlight the importance of choosing that comparator carefully, so a beneficial effect is not missed just because the standard treatment does far better in a specific subgroup than it does in an average population," said Camidge. "This information could prevent the current crizotinib development plans from tripping over an unsuspected hurdle and helping to ensure that good new drugs get licensed when they should."

Knowing there is an established drug that could produce results comparable to the latest targeted therapies such as crizotinib may also help ALK-positive patients around the world. "These results suggest that if you are ALK positive and you don't have access to the experimental drug crizotinib then think about trying pemetrexed instead. It will also be very interesting to see if pemetrexed works as well in ALK positive patients after the crizotinib stops working," he said.

The discovery may even help to identify these rare ALK positive patients in the first place.

"Although good responses can occur in other subtypes of lung cancer, if you or someone you know is having a gang-buster response to pemetrexed and they haven't already been tested for ALK getting tested is probably the next thing to do," said Camidge.

The CU Cancer Center is an international leader in the molecular testing of lung tumors. In early 2008, the center started testing everyone with lung cancer for genetic mutations. Initially they only tested for two mutations, but now they test for 10 different molecular subtypes of lung cancer, including ALK.

"We test all our lung cancer patients at the Cancer Center. We dec
'/>"/>

Contact: Erika Matich
erika.matich@ucdenver.edu
720-848-7852
University of Colorado Denver
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Stethoscope App gives iPhone New Clinical Skills
2. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
3. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
4. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
5. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
6. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
7. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
8. TeraMedica Launches Evercore – Clinical Enterprise Suite 5.0 Now on Linux
9. Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options
10. MedQuist Launches EHR Integration for Dictations Associated with Template-based Clinical Documentation
11. Greenway Medical Technologies Donates Electronic Health Record, Clinical Research and Revenue Cycle Solutions to Northern Kentucky University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... London, UK (PRWEB) May 22, 2015 ... the leading treatment option for chronic obstructive pulmonary ... UK’s GlaxoSmithKline plc and AstraZeneca plc as well ... for market share and position. But will market ... from the already well-entrenched products to completely new ...
(Date:5/22/2015)... Carnegie Science Center and Allegheny ... to develop BodyTech, a dynamic, three-pronged health and science ... new exhibit at the Science Center called BodyWorks, the ... traveling science show, Anatomy Adventure, which will hit the ... to explore a wide range of topics surrounding health ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship ... Drobeck is in his second year of racing in the ... Missoula Fire Department in Missoula, MT. He entered the triathlon ... his career, he has had 15 1st Place finishes. In ... finishes in all seven of his 2014 races, including two ...
(Date:5/22/2015)... May 22, 2015 The ... Dental announces that they are now offering complimentary ... other dental treatments. At consultations, patients can discuss ... regarding what certain treatments can achieve and whether ... during this initial appointment. If treatments are chosen, ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 A ... at the American Society of Clinical Oncology (ASCO)’s ... improved survival rates for those patients who received ... regimen of pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, Inc.) is ... and it is already routinely used to treat ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2
... Pure Power Mouthguard ... , ... December 4, 2009 -- Miami dentist Dr. H.A. Nassery contributes to local athletic ... to patients. He successfully diagnosed and treated Ashley Kimmel, a student at Miami Country Day ...
... 2-D images represent, researchers say , FRIDAY, Dec. 4 ... monkeys they know, proving that they can both detect ... them before, researchers report. , The study also shows ... a photograph, the scientists authors noted. , The findings, ...
... However, benefits are not clear enough to recommend its ... News) -- Cancer patients, glaucoma patients and others can ... shows that it can help multiple sclerosis (MS) patients ... hallmark of the debilitating autoimmune disease. , "The therapeutic ...
... , LOS ANGELES, Dec. 4 Yogen Fruz , the ... holiday themed "NUmixes" -- Yog-Nog and Mint Chocolate ... unveiled at Yogen Fruz stores across North America. Yogen Fruz,s low-calorie ... dessert alternative to indulge in this holiday season. , ...
... , BOSTON and HOUSTON, Dec. 4 AES Annual ... announced today that Vagus Nerve Stimulation (VNS) Therapy , the ... will be featured in 14 presentations at the American Epilepsy ... Hynes Convention Center in Boston, Massachusetts. , Robert Elliott, ...
... , ... InhibOx, a leading developer of novel ... MolPort, an innovator in rare chemical trading.,MolPort focuses on developing rare ... we provide this database and its updates to computational chemists at ...
Cached Medicine News:Health News:Miami Dentist Dr. H.A. Nassery Treats Local Teen Golf Star and Helps Improve Her Performance 2Health News:Review Finds Marijuana May Help MS Patients 2Health News:Review Finds Marijuana May Help MS Patients 3Health News:Yogen Fruz Introduces New Holiday Flavors: Yog-Nog and Mint Chocolate Chip 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 3Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
(Date:5/22/2015)... -- According to a new market research ... Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen Species ... Users - Global Forecast to 2020", published by MarketsandMarkets, the ... $736.85 Million by 2020 from $452.36 Million in 2015, ... Browse 71 market data Tables and 90 Figures spread ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... 60 percent of moderate to severe patients achieved ... remission at Week 10,in data from a 54-week ... (ACG) Annual Scientific Meeting, ORLANDO, Fla., Oct. ... prospective study investigating endoscopic improvement in Crohn,s,disease (CD) ...
... Pharmacokinetic Characteristics of Naltrexone SR Associated with ... Better Tolerability in Clinical Trials ... OREX ), a biopharmaceutical company focused on the ... presented,data showing the investigational drug, Contrave(R) (naltrexone SR /,bupropion ...
Cached Medicine Technology:CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5
The CryoSurgery console is the control center for CryoCath's surgical probe. It is a modular system made up of a console control unit and a tank dolly system. The system can be used as a unit or in s...
... developed a minimally invasive cryocatheter to ... delivers a very high level of ... site precision, minimal tissue disruption, and ... ,Freezor is a flexible, single-use, minimally ...
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available....
... The PORTERFIELD catheter incorporates six electrodes which ... from a single catheter. Positioned in the ... while recording atrial electrograms. The catheter may ... apex for atrial recording and ventricular pacing ...
Medicine Products: